Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®
Clearside Biomedical, Inc. (CLSD)
Last clearside biomedical, inc. earnings: 3/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.clearsidebio.com/investor-overview
Company Research
Source: GlobeNewswire
- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery - - Current Clinical Evidence and Physician Experience Support SCS Injection as a Safe and Effective Method for Delivering Retinal and Choroidal Therapeutics - ALPHARETTA, Ga., May 21, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that RETINA®, The Journal of Retinal and Vitreous Diseases, has published new guidelines that represent best practices for injection into the suprachoroidal space. The publication, entitled, “Suprachoroidal Space Injection Technique: Expert Panel Guidance” was co-authored by 16 practicing retinal physicians led by Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, Houston, TX. The guidance was developed based on current published evidence and
Show less
Read more
Impact Snapshot
Event Time:
CLSD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLSD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLSD alerts
High impacting Clearside Biomedical, Inc. news events
Weekly update
A roundup of the hottest topics
CLSD
News
- Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting [Yahoo! Finance]Yahoo! Finance
- Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit MeetingGlobeNewswire
- Shareholders in Clearside Biomedical (NASDAQ:CLSD) are in the red if they invested three years ago [Yahoo! Finance]Yahoo! Finance
- Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA® [Yahoo! Finance]Yahoo! Finance
- Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $4.00 price target on the stock.MarketBeat
CLSD
Earnings
- 5/9/24 - Miss
CLSD
Sec Filings
- 5/15/24 - Form 4
- 5/10/24 - Form S-8
- 5/10/24 - Form 10-Q
- CLSD's page on the SEC website